Rein Therapeutics (RNTX) Stock Price, News & Analysis

Company Overview

Rein Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for serious diseases with significant unmet medical needs. The company’s research and development activities are centered on fibrotic diseases, in which excessive scar tissue can impair the function of organs and lead to progressive illness.

Rein Therapeutics’ lead investigational program is RNTX-001, an experimental therapy being developed for pulmonary fibrosis and potentially other fibrotic conditions. The company is evaluating the candidate through clinical development and related research, with the goal of creating treatments that address the underlying processes associated with fibrosis.

As a development-stage biopharmaceutical company, Rein Therapeutics does not currently operate a broad commercial product portfolio. Its activities are primarily focused on advancing its pipeline through research, clinical studies, regulatory interactions and potential future partnerships. Publicly available information provides limited detail about the company’s operating geographies and current leadership.

Key Stats

• Today's Range: $0.77 to $0.82
• 50-Day Range: $0.70 to $0.89
• 52-Week Range: $0.69 to $2.18
• Volume: 441,403 shs
• Average Volume: 370,458 shs
• Market Capitalization: $66.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Rein Therapeutics Stock Analysis - MarketRank™

Rein Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 499th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Rein Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Rein Therapeutics has a consensus price target of $6.00, representing about 678.9% upside from its current price of $0.77.

Amount of Analyst Coverage

Rein Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Rein Therapeutics are expected to decrease in the coming year, from ($0.47) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rein Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rein Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.76% of the float of Rein Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rein Therapeutics has a short interest ratio ("days to cover") of 1.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rein Therapeutics has recently decreased by 12.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rein Therapeutics does not currently pay a dividend.

Dividend Growth

Rein Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for RNTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Rein Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rein Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Rein Therapeutics is held by insiders.

Percentage Held by Institutions

90.89% of the stock of Rein Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RNTX
• CIK: 1420565
• Web: www.reintx.com
• Phone: (737) 802-1989
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Rein Therapeutics: $6.00
• High Price Target: $8.00
• Low Price Target: $4.00
• Potential Upside/Downside: +678.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -63.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.27
• Quick Ratio: 4.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.06 per share
• Price / Cash Flow: 13.90
• Book Value: ($1.07) per share
• Price / Book: -0.72

Miscellaneous

• Outstanding Shares: 86,267,000
• Free Float: 84,973,000
• Market Cap: $66.45 million
• Optionable: N/A
• Beta: 1.37